Essential Role for Endocytosis in the Growth Factor-stimulated Activation of ERK1/2 in Endothelial Cells

被引:53
作者
Gourlaouen, Morgane [1 ]
Welti, Jonathan C. [1 ]
Vasudev, Naveen S. [1 ]
Reynolds, Andrew R. [1 ]
机构
[1] Inst Canc Res, Breakthrough Breast Canc Res Ctr, Tumour Biol Team, London SW3 6JB, England
关键词
TYROSINE KINASE INHIBITOR; SIGNAL-TRANSDUCTION; ANTIANGIOGENESIS THERAPY; TUMOR ANGIOGENESIS; TARGETED THERAPY; FACTOR RECEPTOR; PROTEIN-KINASE; GENE DELIVERY; SOLID TUMORS; PHASE-I;
D O I
10.1074/jbc.M112.446401
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vascular endothelial growth factor (VEGF) stimulates angiogenesis by binding to VEGF receptor 2 (VEGFR2) on endothelial cells (ECs). Downstream activation of the extracellular related kinases 1/2 (ERK1/2) is important for angiogenesis to proceed. Receptor internalization has been implicated in VEGFR2 signaling, but its role in the activation of ERK1/2 is unclear. To explore this question we utilized pitstop and dynasore, two small molecule inhibitors of endocytosis. First, we confirmed that both inhibitors block the internalization of VEGFR2 in ECs. We then stimulated ECs with VEGF in the presence and absence of the inhibitors and examined VEGFR2 signaling to ERK1/2. Activation of VEGFR2 and C-Raf still occurred in the presence of the inhibitors, whereas the activation of MEK1/2 and ERK1/2 was abrogated. Therefore, although internalization is not required for activation of either VEGFR2 or C-Raf in ECs stimulated with VEGF, internalization is necessary to activate the more distal kinases in the cascade. Importantly, inhibition of internalization also prevented activation of ERK1/2 when ECs were stimulated with other pro-angiogenic growth factors, namely fibroblast growth factor 2 and hepatocyte growth factor. In contrast, the same inhibitors did not block ERK1/2 activation in fibroblasts or cancer cells stimulated with growth factors. Finally, we show that these small molecule inhibitors of endocytosis block angiogenesis in vitro and in vivo. Therefore, receptor internalization may be a generic requirement for pro-angiogenic growth factors to activate ERK1/2 signaling in human ECs, and targeting receptor trafficking may present a therapeutic opportunity to block tumor angiogenesis.
引用
收藏
页码:7467 / 7480
页数:14
相关论文
共 64 条
  • [1] Role of Raf in vascular protection from distinct apoptotic stimuli
    Alavi, A
    Hood, JD
    Frausto, R
    Stupack, DG
    Cheresh, DA
    [J]. SCIENCE, 2003, 301 (5629) : 94 - 96
  • [2] VEGF internalization is not required for VEGFR-2 phosphorylation in bioengineered surfaces with covalently linked VEGF
    Anderson, Sean M.
    Shergill, Bhupinder
    Barry, Zachary T.
    Manousiouthakis, Eleana
    Chen, Tom T.
    Botvinick, Elliot
    Platt, Manu O.
    Iruela-Arispe, M. Luisa
    Segura, Tatiana
    [J]. INTEGRATIVE BIOLOGY, 2011, 3 (09) : 887 - 896
  • [3] Mechanisms of resistance to antiangiogenesis therapy
    Azam, Faisal
    Mehta, Shaveta
    Harris, Adrian L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (08) : 1323 - 1332
  • [4] Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output
    Ballmer-Hofer, Kurt
    Andersson, Anneli E.
    Ratcliffe, Laura E.
    Berger, Philipp
    [J]. BLOOD, 2011, 118 (03) : 816 - 826
  • [5] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
    Batchelor, Tracy T.
    Sorensen, A. Gregory
    di Tomaso, Emmanuelle
    Zhang, Wei-Ting
    Duda, Dan G.
    Cohen, Kenneth S.
    Kozak, Kevin R.
    Cahill, Daniel P.
    Chen, Poe-Jou
    Zhu, Mingwang
    Ancukiewicz, Marek
    Mrugala, Maciej M.
    Plotkin, Scott
    Drappatz, Jan
    Louis, David N.
    Ivy, Percy
    Scadden, David T.
    Benner, Thomas
    Loeffler, Jay S.
    Wen, Patrick Y.
    Jain, Rakesh K.
    [J]. CANCER CELL, 2007, 11 (01) : 83 - 95
  • [6] Modes of resistance to anti-angiogenic therapy
    Bergers, Gabriele
    Hanahan, Douglas
    [J]. NATURE REVIEWS CANCER, 2008, 8 (08) : 592 - 603
  • [7] Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies
    Bottsford-Miller, Justin N.
    Coleman, Robert L.
    Sood, Anil K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (32) : 4026 - 4034
  • [8] HEPATOCYTE GROWTH-FACTOR IS A POTENT ANGIOGENIC FACTOR WHICH STIMULATES ENDOTHELIAL-CELL MOTILITY AND GROWTH
    BUSSOLINO, F
    DIRENZO, MF
    ZICHE, M
    BOCCHIETTO, E
    OLIVERO, M
    NALDINI, L
    GAUDINO, G
    TAMAGNONE, L
    COFFER, A
    COMOGLIO, PM
    [J]. JOURNAL OF CELL BIOLOGY, 1992, 119 (03) : 629 - 641
  • [9] Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way
    Carmeliet, Peter
    De Smet, Frederik
    Loges, Sonja
    Mazzone, Massimiliano
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (06) : 315 - 326
  • [10] Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
    Casanovas, O
    Hicklin, DJ
    Bergers, G
    Hanahan, D
    [J]. CANCER CELL, 2005, 8 (04) : 299 - 309